Skip to main content
. 2017 Jan-Feb;21(1):210–230. doi: 10.4103/2230-8210.196029

Figure 4.

Figure 4

Efficacy of sodium–glucose co-transporter 2 inhibitors in clinical studies.[72,73] Cana: Canagliflozin, Dapa: Dapagliflozin, DPP-4i: Dipeptidyl peptidase 4 inhibitor, Empa: Empagliflozin, FPG: Fasting plasma glucose, GLP-1 RA: Glucagon-like peptide 1 receptor agent, INS: Insulin, MET: Metformin, SGLT2i: Sodium–glucose transporter inhibitor, SU: Sulfonylurea, TZD: Thiazolidinedione